Hou Gang, Chen Biying, Xu Wenbin, Zhao Huiqing, Liu Kaihua, Yao Hui
Department of Orthopaedics, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510530, P.R. China.
Oncol Lett. 2018 May;15(5):7884-7888. doi: 10.3892/ol.2018.8307. Epub 2018 Mar 20.
The aim of the present study was to investigate the expression of cell division cycle gene 2 () in osteosarcoma tissues and its clinical significance. Specimens of cancer tissues, paracancerous tissues and serum from 47 patients hospitalized at the Department of Orthopedics at The Third Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) from January, 2010 to January, 2015 and serum from 35 normal subjects were collected. The expression of CDC2 mRNA was evaluated using quantitative polymerase chain reaction (RT-PCR) and the relationship between CDC2 protein expression and clinical features of patients with osteosarcoma was analyzed. There was a significant difference in the expression levels of CDC2 between cancer (2.31±0.306) and paracancerous tissues (0.91±0.251) (P<0.05), and there was a difference in the expression of CDC2 in serum between patients (1.58±0.149) and the normal control group (0.67±0.136). Receiver operating characteristic (ROC) curve analysis indicated that CDC2 was of great value in the diagnosis of osteosarcoma. The expression of CDC2 was closely related to the tumor diameter (P<0.05), World Health Organization classification (P<0.05) and KPS score (P<0.05). However, there was no significant association between the expression of CDC2 and factors including age and sex (both P>0.05). The high expression of CDC2 was closely related to the lower survival rate in patients with osteosarcoma (P<0.05). The increase of the tumor-node-metastasis (TNM) staging of osteosarcoma and the high expression of CDC2 are the risk factors affecting the prognosis of osteosarcoma patients (P<0.05), and Cox regression analysis showed that the expression level of CDC2 was a risk factor affecting the prognosis of osteosarcoma patients (P<0.05). The results indicate that CDC2 is highly expressed in osteosarcoma and may be a biomarker to predict the occurrence, development and prognosis of osteosarcoma.
本研究旨在探讨细胞分裂周期基因2（）在骨肉瘤组织中的表达及其临床意义。收集了2010年1月至2015年1月在中山大学附属第三医院（中国广州）骨科住院的47例患者的癌组织、癌旁组织标本及血清，以及35例正常受试者的血清。采用定量聚合酶链反应（RT-PCR）评估CDC2 mRNA的表达，并分析CDC2蛋白表达与骨肉瘤患者临床特征之间的关系。癌组织（2.31±0.306）和癌旁组织（0.91±0.251）中CDC2的表达水平存在显著差异（P<0.05），患者血清（1.58±0.149）和正常对照组（0.67±0.136）中CDC2的表达也存在差异。受试者工作特征（ROC）曲线分析表明，CDC2在骨肉瘤诊断中具有重要价值。CDC2的表达与肿瘤直径（P<0.05）、世界卫生组织分类（P<0.05）和KPS评分（P<0.05）密切相关。然而，CDC2的表达与年龄和性别等因素之间无显著关联（均P>0.05）。CDC2的高表达与骨肉瘤患者较低的生存率密切相关（P<0.05）。骨肉瘤肿瘤-淋巴结-转移（TNM）分期的增加和CDC2的高表达是影响骨肉瘤患者预后的危险因素（P<0.05），Cox回归分析表明，CDC2的表达水平是影响骨肉瘤患者预后的危险因素（P<0.05）。结果表明，CDC2在骨肉瘤中高表达，可能是预测骨肉瘤发生、发展及预后的生物标志物。
